Blog
Feedback
schliessen

Filtern

 

Bibliotheken

Logo der Bibliothek

Logo FID Pharmazie PubPharm Discovery System Universitätsbibliothek Braunschweig Institut für Informationssysteme

Colorectal surgery obesity-related morbidity during COVID-19

Tocilizumab, a monoclonal antiinterluekin-6 receptor antibody, has been empirically used in the treatment of cytokine release syndrome associated with severe coronavirus disease 2019 infections. The efficacy and safety of these medications for these patients is unknown. The purpose of this report was to present a case of acute large bowel perforation in a morbidly obese patient with coronavirus disease 2019 pneumonia who received empiric Tocilizumab. This case report analyzes the risks of acute large bowel perforation after using this medication empirically and discusses the appropriate management of this adverse event

Year of Publication: 2020
Contained in: Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery Vol. 16, No. 9 (2020), p. 1372-1375
All journal articles: Search for all articles in this journal
Language: English
Contributors: Montorfano, Lisandro | Author
Miret, Rafael
Rahman, Asad Ur
Alonso, Mileydis
Maron, David J
Roy, Mayank
Ferri, Francisco
Bejarano, Pablo
Wexner, Steven D
Full text access:
Electronic availability is being checked...
Links: Full Text (dx.doi.org)
Keywords: Bowel perforation
COVID-19
Case Reports
Colonic perforation
Corticosteroids
I031V2H011
IL-6
Journal Article
SARS-CoV-2 coronavirus
Tocilizumab
Video-Audio Media
tocilizumab
Additional Keywords: *Betacoronavirus
Antibodies, Monoclonal, Humanized
Cecal Diseases
Coronavirus Infections
Cytokine Release Syndrome
Female
Humans
Intestinal Perforation
Middle Aged
Obesity, Morbid
Pandemics
Pneumonia, Viral
ISSN: 1878-7533
Note: Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Notes: Date Completed 09.09.2020
Date Revised 18.09.2020
published: Print-Electronic
Citation Status MEDLINE
Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
PMID:
    32723601
Physical Description: Online-Ressource
ID (e.g. DOI, URN): 10.1016/j.soard.2020.06.011
more publication details ...

Associated Publications

  • Associated records are being queried...
more (+)
Internes Format
LEADER 04059nma a2200925 c 4500
001 NLM313918341
003 DE-601
005 20200918213852.0
007 cr uuu---uuuuu
008 200729s2020 000 0 eng d
024 7 |a 10.1016/j.soard.2020.06.011  |2 doi 
028 5 2 |a pubmed20n1343.xml 
035 |a S1550-7289(20)30331-2 
035 |a (DE-599)NLM32723601 
040 |b ger  |c GBVCP 
041 0 |a eng 
100 1 |a Montorfano, Lisandro 
245 1 0 |a Colorectal surgery obesity-related morbidity during COVID-19  |h Elektronische Ressource 
300 |a Online-Ressource 
500 |a Date Completed 09.09.2020 
500 |a Date Revised 18.09.2020 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
500 |a Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine 
520 |a Copyright © 2020 American Society for Bariatric Surgery. Published by Elsevier Inc. All rights reserved. 
520 |a Tocilizumab, a monoclonal antiinterluekin-6 receptor antibody, has been empirically used in the treatment of cytokine release syndrome associated with severe coronavirus disease 2019 infections. The efficacy and safety of these medications for these patients is unknown. The purpose of this report was to present a case of acute large bowel perforation in a morbidly obese patient with coronavirus disease 2019 pneumonia who received empiric Tocilizumab. This case report analyzes the risks of acute large bowel perforation after using this medication empirically and discusses the appropriate management of this adverse event 
611 2 7 |a Case Reports  |2 gnd 
611 2 7 |a Journal Article  |2 gnd 
611 2 7 |a Video-Audio Media  |2 gnd 
653 2 |a Antibodies, Monoclonal, Humanized  |6 D061067  |a *adverse effects  |6 Q000009 
653 2 |a *Betacoronavirus  |6 D000073640 
653 2 |a Cecal Diseases  |6 D002429  |a diagnosis  |6 Q000175  |a *etiology  |6 Q000209  |a surgery  |6 Q000601 
653 2 |a Coronavirus Infections  |6 D018352  |a complications  |6 Q000150  |a diagnosis  |6 Q000175  |a *drug therapy  |6 Q000188 
653 2 |a Cytokine Release Syndrome  |6 D000080424  |a etiology  |6 Q000209  |a prevention & control  |6 Q000517 
653 2 |a Female  |6 D005260 
653 2 |a Humans  |6 D006801 
653 2 |a Intestinal Perforation  |6 D007416  |a diagnosis  |6 Q000175  |a *etiology  |6 Q000209  |a surgery  |6 Q000601 
653 2 |a Middle Aged  |6 D008875 
653 2 |a Obesity, Morbid  |6 D009767  |a *complications  |6 Q000150 
653 2 |a Pandemics  |6 D058873 
653 2 |a Pneumonia, Viral  |6 D011024  |a complications  |6 Q000150  |a diagnosis  |6 Q000175  |a *drug therapy  |6 Q000188 
655 7 |a Bowel perforation  |2 gnd 
655 7 |a COVID-19  |2 gnd 
655 7 |a Colonic perforation  |2 gnd 
655 7 |a Corticosteroids  |2 gnd 
655 7 |a IL-6  |2 gnd 
655 7 |a SARS-CoV-2 coronavirus  |2 gnd 
655 7 |a Tocilizumab  |2 gnd 
655 7 |a Antibodies, Monoclonal, Humanized  |2 gnd 
655 7 |a tocilizumab  |2 gnd 
655 7 |a I031V2H011  |2 gnd 
689 0 0 |A f  |a Case Reports 
689 0 1 |A f  |a Journal Article 
689 0 2 |A f  |a Video-Audio Media 
689 0 |5 DE-601 
689 1 0 |a Bowel perforation 
689 1 1 |a COVID-19 
689 1 2 |a Colonic perforation 
689 1 3 |a Corticosteroids 
689 1 4 |a IL-6 
689 1 5 |a SARS-CoV-2 coronavirus 
689 1 6 |a Tocilizumab 
689 1 |5 DE-601 
689 2 0 |a Antibodies, Monoclonal, Humanized 
689 2 1 |a tocilizumab 
689 2 2 |A r  |a I031V2H011 
689 2 |5 DE-601 
700 1 |a Miret, Rafael 
700 1 |a Rahman, Asad Ur 
700 1 |a Alonso, Mileydis 
700 1 |a Maron, David J 
700 1 |a Roy, Mayank 
700 1 |a Ferri, Francisco 
700 1 |a Bejarano, Pablo 
700 1 |a Wexner, Steven D 
773 0 8 |i in  |t Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery  |g Vol. 16, No. 9 (2020), p. 1372-1375  |q 16:9<1372-1375  |w (DE-601)NLM164933964  |x 1878-7533 
856 4 1 |u http://dx.doi.org/10.1016/j.soard.2020.06.011  |3 Volltext 
912 |a GBV_NLM 
951 |a AR 
952 |d 16  |j 2020  |e 9  |b 24  |c 09  |h 1372-1375